Eton Pharmaceuticals Inc. Stock News

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informa

Zacks Investment Research downgraded shares of Harrow Health (NASDAQ:HROW) from a buy rating to a hold rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield []

Eton Pharmaceuticals Inc. (NASDAQ:ETON) concluded the trading at $3.71 on Friday, December 03 with a rise of 0.82% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.68 and 5Y monthly beta was reading 1.26 with its price kept floating in the Eton Pharmaceuticals Inc. (ETON): Major Improvements, Worth A Look Read More »

Belvedere Trading LLC acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 20,829 shares of the companys stock, valued at approximately $107,000. Belvedere Trading LLC owned 0.08% of Eton Pharmaceuticals as []

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 720,000 shares, an increase of 36.0% from the October 31st total of 529,400 shares. Based on an average daily trading volume, of 345,500 shares, the days-to-cover ratio is currently 2.1 []

Price T Rowe Associates Inc. MD bought a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 217,782 shares of the companys stock, valued at approximately $1,342,000. Several other institutional []

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Research analysts at B. Riley lowered their FY2022 earnings per share estimates for Eton Pharmaceuticals in a research note issued to investors on Monday, November 22nd. B. Riley analyst J. Walsh now expects that the company will post earnings per share of $0.13 for the year, down from their previous []

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) major shareholder Opaleye Management Inc. sold 25,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, November 17th. The shares were sold at an average price of $4.67, for a total transaction of $116,750.00. The transaction was disclosed in a document filed with the SEC, which is available []

Eton Pharmaceuticals Inc. (NASDAQ:ETON)s traded shares stood at 0.32 million during the last session. At the close of trading, the stocks price was $4.56, to imply an increase of 0.88% or $0.04 in intraday trading. The ETON shares 52-week high remains $10.30, putting it -125.88% down since that peak but still an impressive 11.62% since Eton Pharmaceuticals Inc. (NASDAQ: ETON) Friday Up 11.62% From The Lows, What Happens Next Read More »

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) major shareholder Opaleye Management Inc. sold 25,000 shares of the firm’s stock in a transaction on Wednesday, November 17th. The shares were sold at an average price of $4.67, for a total transaction of $116,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through […]

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) major shareholder Opaleye Management Inc. sold 3,000 shares of the stock in a transaction dated Monday, November 15th. The stock was sold at an average price of $4.80, for a total transaction of $14,400.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC []

Eton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q3 2021 Results - Earnings Call Transcript